VISFATIN/NAMPT/PBCEF and cytokine concentration in multiple sclerosis patients compared to healthy subjects

European Journal of Inflammation

Volumn 9, Issue 1, 2011, Pages 31-37

  Mirzaei, K ^a   Hossein Nezhad, Arash ^a   Mokhtari, F ^a   Najmafshar, A ^a   Khoshniat Nikoo, M ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hs CRP; IL 1 ; Multiple sclerosis; TNF ; Visfatin

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 1BETA; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ADULT; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DIET RESTRICTION; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; PROTEIN BLOOD LEVEL; RECURRENT DISEASE;

EID: 81755169952     PISSN: 1721727X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1721727X1100900105     Document Type: Article

References (27)

1. Kasper L, Shoemaker J. Multiple sclerosis immunology: The healthy immune system vs the MS immune system. Neurology 2010; 5:2-8.
2. Hossein-Nezhad A, Nikoo M, Mirzaei K, Mokhtarei F, Meybodi H. Comparison of the bone turn-over markers in patients with multiple sclerosis and healthy control subjects. Eur J Inflamm 2010; 8:67-73.
3. Librau R, Singer S, McDevitt H. Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995; 16:4-48.
4. Lassmann H. Models of multiple sclerosis: new insights into pathophysiology and repair. Curr Opin Neurol 2008; 21:242-7. (Pubitemid 351653971)
5. Stockinger B, Veldhoen M. Differentiation and function of Th17 T cells. Curr Opin Immunol 2007; 19:281-6. (Pubitemid 46687011)
6. Bruzzone S, Fruscione F, Morando S, et al. Catastrophic NAD+ depletion in activated T lymphocytes through Nampt inhibition reduces demyelination and disability in EAE. PLoS One 2009 4e:7897.
7. Rongvaux A, Galli M, Denanglaire S, et al. Nicotinamide phosphoribosyl Transferase/pre-B cell colony-enhancing factor/visfatin is required for lymphocyte development and cellular resistance to genotoxic stress. J Immunol 2008; 181:4685-95.
8. Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD, Marshall JC. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004; 113:1318-27. (Pubitemid 39069931)
9. Revollo J, Körner A, Mills K, et al. Nampt/PBEF/visfatin regulates insulin secretion in β cells as a systemic NAD biosynthetic enzyme. Cell Metab 2007; 6:363-75. (Pubitemid 350011996)
10. Rongvaux A, Shea R, Mulks M, et al. Pre-B-cell colony-enhancing factor, whose expression is upregulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol 2002; 32:3225-34. (Pubitemid 35414880)
11. Kaneko S, Wang J, Kaneko M, et al. Protecting axonal degeneration by increasing nicotinamide adenine dinucleotide levels in experimental autoimmune encephalomyelitis models. J Neurosci 2006; 26:9794-804. (Pubitemid 44427718)
12. Penberthy WT, Tsunoda I. The importance of NAD in multiple sclerosis. Curr Pharm Des 2009; 15:64-99.
13. Link H. The cytokine storm in multiple sclerosis. Mult. Scler 1998; 4:12-5. (Pubitemid 28077430)
14. McDonald W, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50:121-7.
15. Kurtzke J. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33:1444-52. (Pubitemid 14237132)
16. Sasaki Y, Araki T, Milbrandt J. Stimulation of nicotinamide adenine dinucleotide biosynthetic pathways delays axonal degeneration after axotomy. J Neurosci 2006; 26:8484-91. (Pubitemid 44316176)
17. Mirzaei K, Hossein-Nezhad A, Javad Hosseinzadeh-Attar M, et al. Visfatin genotype may modify the insulin resistance and lipid profile in type 2 diabetes patients. Minerva Endocrinol 2009; 34:273-9.
18. Lambert C, Lee Archer R, Evans W. Body composition in ambulatory women with multiple sclerosis. Arch Phys Med Rehabil 2002; 83:1559-61. (Pubitemid 35304133)
19. Ghadirian P, Jain M, Ducic S, Shatenstein B, Morisset R. Nutritional factors in the aetiology of multiple sclerosis: a case-control study in Montreal, Canada. Int J Epidemiol 1998; 27:845-52. (Pubitemid 28504973)
20. Rocha V, Folco E, Sukhova G, et al. Interferon-gamma, a Th1 cytokine, regulates fat inflammation: a role for adaptive immunity in obesity. Circ Res 2008; 103:467-76.
21. Jia S, Li Y, Parodo J, et al. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004; 113:1318-27. (Pubitemid 39069931)
22. Kern P, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001; 280:745-51.
23. Carrieri P, Maiorino A, Provitera V, Soscia E, Perrella O. Cytokines in the pathogenesis of multiple sclerosis. Acta Neurol (Napoli) 1992; 14:333-41.
24. Dujmovic I, Mangano K, Pekmezovic T, et al. The analysis of IL-1 beta and its naturally occurring inhibitors in multiple sclerosis: The elevation of IL-1 receptor antagonist and IL-1 receptor type II after steroid therapy. J Neuroimmunol 2009; 207:101-6.
25. Soilu-Hänninen M, Koskinen J, Laaksonen M, Hänninen A, Lilius E, Waris M. High sensitivity measurement of CRP and disease progression in multiple sclerosis. Neurology 2005; 65:153-5. (Pubitemid 40967796)
26. De Jong B, Huizinga T, Bollen E, et al. Production of IL-1beta and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis. J Neuroimmunol 2002; 126:172-9. (Pubitemid 34521742)
27. Moschen A, Geiger S, Gerner R, Tilg H. Pre-B cell colony enhancing factor/NAMPT/visfatin and its role in inflammation-related bone disease. Mutat Res 2009; 690:95-101.